News

Frank Magliochetti on the Move!

2019

Frank Magliochetti owes his professional success to his expertise in two areas: medicine and finance. After obtaining a BS in pharmacy from Northeastern University, he stayed on to enroll in the Masters of Toxicology program. He later specialized in corporate finance, receiving an MBA from The Sawyer School of Business at Suffolk University. His educational background includes completion of the Advanced Management Program at Harvard Business School and the General Management Program at Stanford Business School. Frank Magliochetti has held senior positions at Baxter International, Kontron Instruments, Haemonetics Corporation, and Sandoz. Since 2000, he has been a managing partner at Parcae Capital, where he focuses on financial restructuring and interim management services for companies in the healthcare, media, and alternative energy industries. Earlier this year, he was appointed chairman of the board at Grace Health Technology, a company providing an enterprise solution for the laboratory environment.

Mr. Frank Magliochetti MBA
Managing Partner
Parcae Capital

www.parcaecapitalcorp.com
www.frankmagliochettiNews.com

Twitter:  https://twitter.com/F_Magliochetti1

Archives:

The summer months were quite busy for the managing partner at Parcae Capital  Frank Magliochetti.

Frank was keeping  the content on Absolute Day Traders  up to date with hot pick hit company OPKO Health.  The ongoing posts featuring Opko Healthone of Absolute Day Trader Picks  pick hit companies started hitting it big late August and fast became trending on numerous sites as a company to have on your watch list.    Frank was way out in front of this company for months leading up to it making headlines Frank was posting about the important activity at OPKO.    – Keep an eye on the pick hits from Frank  on Absolute Day Traders! !

Frank took some time to co-host the popular internet business radio show MYOB on the UR Business Network with show creator and UR Business Network  founder Rick Brutti.

Frank had on two innovative pioneers in their respective fields as guests both made for some interesting and lively conversation.

Meet Peter Weinstein founder and SEO of  One3 IP.

LISTEN TO THE INTERVIEW – CLICK HERE!

Here is some information Boston Financial Guide curated from the One3 IP  website to share with you while listening to the interview. We urge you to visit their website for more details about  One3 IP by clicking HERE.

ONE3IP_FRANKBAGLIOCHETTI

About Us

One3 IP Management was founded based on several key principles that can be summed up as, One3 IP guarantees that it will focus on our clients’ needs and will continually strive to provide our clients the best service, the best results at a price that our clients can afford.  In a nutshell, our clients’ needs will always come first.  Contact One3 IP and let us show you how it is done.

Core Values

One3 IP Management views your intellectual property differently than general practice and patent law firms. To One3 IP, its clients are partners, whose success is One3 IP’s goal. One3 IP is driven to bring the highest quality work to its clients by focusing on the client’s needs.

Our Clients

No matter what industry or technology your company practices, One3 IP can handle your intellectual property and licensing needs. One3 IP represents clients in many different industries around the world, including in biotechnology, pharmaceuticals, medical information, medical device, hardware and software, personal products, sportswear and other technology fields.

Who We Are

One3 IP is an intellectual property management company that works as a partner with its clients to help them protect their intellectual property in a manner that obtains the broadest patent protection available, while also helping its clients establish, implement and follow through on the procedures necessary to protect non-patented trade secrets in a legally enforceable manner. By doing this, One3 IP is able to maximize the monetary and protective value of its clients intellectual property. One3 IP also handles its clients licensing needs, from simple Confidentiality Agreements to complex Research and Development Collaboration Agreements. Let One3 IP be your company’s partner. One3 IP does all this in a cost effective manner that fits within its client’s budget.

Meet  Xenetic CEO Scott Maguire and listen to what Xenetic is doing and how it may  impact the Boston Financial landscape.

CLICK HERE – to listen to the interview!

xenetic_bioscience-Logo

Xenetic is a leading UK-based bio pharmaceutical company providing leading-edge expertise in the development of a whole new generation of drugs, cancer therapies and vaccines.

Working with some of the largest pharmaceutical organisations in the world, Xenetic provides specialist delivery solutions to improve the efficacy and performance of drugs and vaccines in a number of key medical areas including oncology.

We are also actively developing our own pipeline of next generation biotherapeutics based on our proprietary PolyXen,Oncohist and ImuXen platform technologies.

Here are some of the facts curated by Boston Financial Guide from  the Xenetic website

Product Pipeline

Protein drugs and vaccines

Xenetic’s biopharmaceutical pipeline contains a range of product candidates which are currently under development either in-house or with biotechnology and pharmaceutical partners.  The products in Xenetic’s pipeline have a multi-billion dollar market potential.

Frank Magliochetti is managing partner at Parcae Capital.

Parcae Capital offers personalized investment banking services for emerging growth companies. We specialize in finding companies which have leading edge technology, services or intellectual property in the healthcare, media and alternative energy space. We assist both public and private companies in preparing to raise private and public capital for all phases of growth. Parcae Capital also offers comprehensive assistance in mergers, acquisitions and related services. Our work out group specializes in business restructuring and recapitalization.